Compare Cytokinetics Inc (CYTK) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs ProShares UltraPro S&P500 — how do they compare? Cytokinetics Inc trades at $82.48 (market cap $11.12B), while ProShares UltraPro S&P500 trades at $144.91. Which is the better fit depends on your goals.
| CYTK | UPRO | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $87.26 | $150.93 |
52-Week Low | $33.23 | $89.29 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
UPRO is trading at $142.72, down 2.35% on the day, with technical indicators showing a bullish bias as moving averages signal strength while oscillators remain neutral. The stock faces immediate resistance at $145 and support at $141. Recent market sentiment reflects cautious optimism around S&P 500 performance, with analysts projecting potential index gains to 8,000 by year-end despite concerns about AI fatigue and elevated valuations.
The outlook for UPRO remains tied to broader market momentum, with earnings season potentially providing the next catalyst. Key risks include market volatility from Fed policy uncertainty and stretched valuations, while institutional positioning suggests continued confidence in large-cap US equities as the primary driver of returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
